CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg, +21

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaMabthera International TrialMedicinePathology +5

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong, +18

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaMedicineRandomised Phase 3Follicular Lymphoma +3

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

John P. Leonard, Marek Trněný, Koji Izutsu, +19

Journal of Clinical Oncology

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

Michael Pfreundschuh, Anthony D. Ho, Eva Cavallin‐Ståhl, +15

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaMaximum TumourMedicineMalignant Blood Disorder +7

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong, +15

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaRituximab Versus RituximabMedicineRandomised Phase 3 +4

Association of social network and social support with health-related quality of life and fatigue in long-term survivors of Hodgkin lymphoma

Andréa Soares, Irène Biasoli, Adriana Scheliga, +5

Supportive Care in Cancer

Social IsolationQuality Of LifeHodgkin LymphomaPatient SupportHealth Behavior +7

CD10 and Bcl‐2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large‐cell lymphoma with very good or very poor prognoses

Irène Biasoli, José Carlos Morais, Adriana Scheliga, +5

Histopathology

Psychometric Properties of the Multidimensional Fatigue Inventory in Brazilian Hodgkin's Lymphoma Survivors

Renata Baptista, Irène Biasoli, Adriana Scheliga, +5

Journal of Pain and Symptom Management

Quality Of LifeLife AssessmentBrazilian HodgkinMultidimensional Fatigue InventoryFatigue Management +5

Validation of the Brazilian Portuguese version of the Medical Outcomes Study-Social Support Survey in Hodgkin's lymphoma survivors

Andréa Soares, Irène Biasoli, Adriana Scheliga, +5

Supportive Care in Cancer

Family MedicineHealth PolicyPatient ExperiencePatient SupportHealth Communication +9

Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin’s disease

Juliane Musacchio, Maria da Glória Carvalho, José Carlos Morais, +4

Sao Paulo Medical Journal